Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
Nature reviews. Cancer (2012) Vol. 12, Iss. 4, pp. 252-264
Open Access | Times Cited: 12406

Showing 1-25 of 12406 citing articles:

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al.
Breast Care (2016) Vol. 11, Iss. 6, pp. 385-390
Open Access | Times Cited: 30388
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 17, pp. 1627-1639
Open Access | Times Cited: 8738
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 2, pp. 123-135
Open Access | Times Cited: 7956
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 26, pp. 2455-2465
Open Access | Times Cited: 7481
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, et al.
The Lancet (2015) Vol. 387, Iss. 10027, pp. 1540-1550
Closed Access | Times Cited: 6056
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, et al.
Nature (2014) Vol. 515, Iss. 7528, pp. 568-571
Open Access | Times Cited: 5905
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 21, pp. 2018-2028
Open Access | Times Cited: 5638
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 26, pp. 2521-2532
Open Access | Times Cited: 5365
Cancer immunotherapy using checkpoint blockade
Antoni Ribas, Jedd D. Wolchok
Science (2018) Vol. 359, Iss. 6382, pp. 1350-1355
Open Access | Times Cited: 5337
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li, Jingyu Fan, Binbin Wang, et al.
Cancer Research (2017) Vol. 77, Iss. 21, pp. e108-e110
Open Access | Times Cited: 4772
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer A. Wargo, et al.
Cell (2017) Vol. 168, Iss. 4, pp. 707-723
Open Access | Times Cited: 4390
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Nature (2017) Vol. 541, Iss. 7637, pp. 321-330
Closed Access | Times Cited: 4315
The future of immune checkpoint therapy
Padmanee Sharma, James P. Allison
Science (2015) Vol. 348, Iss. 6230, pp. 56-61
Closed Access | Times Cited: 4245
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole, Frank J. Slack
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 3, pp. 203-222
Closed Access | Times Cited: 4120
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 20, pp. 1919-1929
Open Access | Times Cited: 3837
Molecular and cellular insights into T cell exhaustion
E. John Wherry, Makoto Kurachi
Nature reviews. Immunology (2015) Vol. 15, Iss. 8, pp. 486-499
Open Access | Times Cited: 3719
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 2, pp. 134-144
Open Access | Times Cited: 3316
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio, et al.
Genome Medicine (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 2996
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Journal of Clinical Investigation (2017) Vol. 127, Iss. 8, pp. 2930-2940
Open Access | Times Cited: 2977
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, et al.
The Lancet (2016) Vol. 389, Iss. 10066, pp. 299-311
Open Access | Times Cited: 2875
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin, et al.
New England Journal of Medicine (2016) Vol. 375, Iss. 9, pp. 819-829
Open Access | Times Cited: 2759
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen, Dallas B. Flies
Nature reviews. Immunology (2013) Vol. 13, Iss. 4, pp. 227-242
Open Access | Times Cited: 2729
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles, Aaron M. Newman, Chih Long Liu, et al.
Nature Medicine (2015) Vol. 21, Iss. 8, pp. 938-945
Open Access | Times Cited: 2704
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado, Carsten Denkert, Sandra Demaria, et al.
Annals of Oncology (2014) Vol. 26, Iss. 2, pp. 259-271
Open Access | Times Cited: 2621
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei, Colm R. Duffy, James P. Allison
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1069-1086
Open Access | Times Cited: 2588
Page 1 - Next Page

Scroll to top